Skip to main content

Table 2 Summary of seroprevalence studies included in the systematic review by year of publication

From: A systematic review on malaria sero-epidemiology studies in the Brazilian Amazon: insights into immunological markers for exposure and protection

Identification (references) Year of publication State Study design Sample sizea Target antigenbc Overall seroprevalence (%) 95% CI
Rodrigues da Silva et al. [34] 2016 Rondônia Cross-sectional 545 PvMSP9-RIRII 58 53.86–62.14
PvMSP9-E795/A808 32.5 28.57–36.43
Sanchez-Arcila et al. [30] 2015 Rondônia Cross-sectional 279 PvMSP119 66 60.44–71.56
PvAMA-1(Picchia pastoris) 63 57.33–68.67
Cunha et al. [28] 2014 Pará Cross-sectional 1330 PfMSP119 25.6 23.25–27.95
PfAMA-1 12.7 10.91–14.49
PvMSP119 36.3 33.72–38.88
PvAMA-1 32.5 29.98–35.02
Ferreira et al. [38] 2014 Rondônia Cross-sectional 253 PvRMC-RBP1 47.1 40.95–53.25
PvRBP1-23-751 60 53.96–66.04
Versiani et al. [41] 2013 Amazonas Cohort 308 PvMSP1 (N-terminus) 35.4 30.06–40.74
Lima Junior et al. [33] 2012 Rondônia Cross-sectional 276 PvMSP119 86.7 82.69–90.71
PvMSP3-alpha 77 72.04–81.96
PvMSP9 76 70.96–81.04
Kano et al. [29] 2012 Amazonas Cross-sectional 432 PvDBP 49.5 44.79–54.21
PvMSP119 86.7 83.5–89.9
Lima Junior et al. [32] 2011 Rondônia Cross-sectional 282 PvMSP3-alpha 78 73.17–82.83
Souza-Silva et al. [40] 2010 Acre Cohort 366 PvDBP 18.6 14.61–22.59
Lima Junior et al. [31] 2008 Rondônia Cross-sectional 306 PvMSP9 74 69.1–78.91
Ladeia-Andrade et al. [27] 2007 Amazonas Cross-sectional 812
778
PvMSP119 66.3d 62.93–69.43
PfMSP119 (Saccharomyces cerevisae) 53.5d 49.96–56.95
Bastos et al. [18] 2007 Acre Cohort 376 PvMSP119 54.3 46.29–59.34
Suarez-Mutis et al. [24] 2007 Amazonas Cross-sectional 98 PvMSP119 46.9 37.02–56.78
Scopel et al. [25] 2007 Acre Cohort 356 PfMSP-2 S20 28.1 23.43–32.77
PfMSP-2 FC27 22.2 17.88–26.52
PfMSP-2 AM89 7.3 4.6–10
PfMSP-2 3D7 6.2 3.69–8.71
PfMSP-2 FUP/CP 6.2 3.69–8.71
Nogueira et al. [39] 2006 Rondônia Cohort 429 N-terminus–PvMSP1 35d 30.6–39.59
PvMSP119 41.5d 36.93–46.21
Tran et al. [37] 2005 Rondônia Cross-sectional 294 PvDBP 67 61.63–72,37
PvRBP-1 66 60.59–71.47
Marcano et al. [15] 2004 Roraima Cross-sectional 101 Pf blood stages (IFAT) 72.1 63.35–80.85
Alexandre et al. [26] 1997 Amazonas Cross-sectional 241 PfR44 26.5e 20.93–32.07
PfAg-T 57.7e 51.43–63.91
Arruda et al. [14] 1996 Pará Cross-sectional 430 PfCS 44f 39.33–48.71
Pf blood stage (IFAT) 68f 63.54–72.36
PvCS 60.1e 55.42–64.68
Pv blood stage (IFAT) 73.2e 68.98–77.36
Ferreira et al. [17] 1994 Rondônia Cohort 50 Pf Exoantigens 30g 17.3–42.7
Pf Somatic Antigens 40g 26.42–53.58
Oliveira-Ferreira et al. [16] 1992 Rondônia Cross-sectional 1617 PfCS (Immunoradiometric) 5.9 4.75–7.05
Pf Blood stage (IFAT) 49.2 46.76–51.64
Kremsner et al. [23] 1992 Acre Cross-sectional 645 PvCS 17.3f 14.33–20.17
PvCS (VK247) 4.8f 3.11–6.39
Jeffery et al. [19] 1975 Mato Grosso Cross-sectional 4270 Pf and Pv blood stage (IFAT) 10.5h 9.58–11.42
  1. aSample size refers to number of participants for whom serology was determined
  2. bIf other serological methods were used instead ELISA, it is shown in parenthesis
  3. cIf other expression systems were used to produce recombinant antigens instead E.coli in fusion with histydine tag (His6) or Glutationa S-transferase (GST), it is shown in parenthesis
  4. dCombined cross-sectional surveys
  5. eAverage seroprevalence in all age groups
  6. fAverage seroprevalence for all cross-sectional surveys
  7. gResults shown for the last survey conducted
  8. hAverage prevalence for both antigens (P. falciparum and P. vivax blood stages) across four surveys